Please login to the form below

Not currently logged in
Email:
Password:

Anker Lundemose appointed CEO of Bionor Pharma

Will lead efforts to develop and commercialise HIV vaccines

Anker Lundemose, Bionor PharmaVaccines specialist Bionor Pharma has appointed Dr Anker Lundemose as its new president and CEO.

The Norway-based biotech, which is focused on peptide-based vaccines for HIV, said Dr Lundemose will take over the role from March 1, when his predecessor Steen Krøyer becomes deputy chairman of the board.

Dr Lundemose has spent many years in the biotech and pharma industry, including spells as CEO of Prosidion, executive VP corporate and business development at OSI Pharmaceuticals and business development director at Novo Nordisk.

He has experience in several mergers and acquisitions, including OSI's acquisition by Astellas in 2010, and has co-founded several biotech companies.

"I am delighted to be joining Bionor Pharma at this crucial point in its development," said Dr Lundemose, referencing the company's three ongoing clinical studies investigating potential HIV vaccines Vacc-4x and Vacc-C5."

He continued: “The two HIV vaccines in combination may have the potential to be part of an eradication strategy within HIV.

"In addition, the company has several other novel targeted vaccine technologies in its pipeline and an excellent R&D team, which I look forward to lead going forward."

Bionor Pharma is also implementing further changes as the company looks to move from a technology-driven company to one focused more on development and commercialisation.

These plans include the departure of co-founder Birger Sørensen as a regular employee.

31st January 2013

From: Research, Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics